Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthLTS:0QYW 65 Days Payable is 69.57 as of Jun. 2026, which is at its 10-year median of 69.57. GuruFocus rates LTS:0QYW with a GF Score™ of 65/100 and a GF Value™ of CHF157.98. The stock has 3 warning signs investors should review. Among 926 Drug Manufacturers companies, Bausch Health ranks worse than 59.83% on this metric.
The historical data trend for Bausch Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Bausch Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bausch Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (LTS:0QYW) has a Days Payable of 69.57 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bausch Health and its competitors. This is near median its historical median of 69.57. Over the past decade, Bausch Health's Days Payable has ranged from 50.39 to 88.90. According to the industry distribution chart, Bausch Health ranks #554 out of 926 companies in the Drug Manufacturers industry, placing it in the top 59.8%.
Is Bausch Health's Days Payable too high?
Bausch Health's current Days Payable of 69.57 is near median its 10-year median of 69.57. Over the past 10 years, this metric has ranged from a low of 50.39 to a high of 88.90. The Drug Manufacturers industry median Days Payable is 90.22. Bausch Health's value of 69.57 is 22.9% below this industry median. Based on the distribution chart, Bausch Health ranks #554 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #554 out of 926 companies for Days Payable. This places Bausch Health in the lower half of its industry. The industry median Days Payable is 90.22. Bausch Health's value of 69.57 is 22.9% below this benchmark. Historically, Bausch Health's own Days Payable has ranged from 50.39 to 88.90 over the past decade. While the company's 10-year median is 69.57 vs. the industry median of 90.22, Bausch Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current Days Payable of 69.57 is 22.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Days Payable is 69.57, which is near median its own 10-year median of 69.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current Days Payable of 69.57. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current Days Payable is 69.57, which is near median its 10-year median of 69.57 and 22.9% below the Drug Manufacturers industry median of 90.22. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current Days Payable is 69.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (LTS:0QYW) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.
Key valuation signals for LTS:0QYW:
Days Payable: 69.57 (near median its 10-year median of 69.57)
GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
Industry Position: 22.9% below the Drug Manufacturers median (#554 of 926)
No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score
Get the complete analysis for LTS:0QYW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QYW has been successfully added to your 
